Rx Import Bill Undercuts FDA Approach To Quality Control, Lilly Exec Testifies
Executive Summary
FDA's process focus in GMP regulation illustrates the importance of manufacturer control over importation into the U.S., Lilly Europe/North America Area Quality Control Leader Nikki Mehringer told the House Commerce/Oversight Subcommittee Oct. 3.
You may also be interested in...
FDA’s 2002 Regulatory Agenda, In Brief
IRB registration: FDA to propose rule requiring institutional review boards to register with the agency. Registration information would include name of institution operating the IRB, detailed contact information for "the senior officer of the institution and IRB chair or contact, the range of active protocols...involving FDA-regulated products reviewed in previous calendar year, and a description of the types of...products reviewed." The rule is intended to "make it easier for FDA to inspect IRBs and to convey information to IRBs," HHS' Unified Agenda for 2002 explains. FDA is also endorsing a voluntary IRB accreditation system...
FDA’s 2002 Regulatory Agenda, In Brief
IRB registration: FDA to propose rule requiring institutional review boards to register with the agency. Registration information would include name of institution operating the IRB, detailed contact information for "the senior officer of the institution and IRB chair or contact, the range of active protocols...involving FDA-regulated products reviewed in previous calendar year, and a description of the types of...products reviewed." The rule is intended to "make it easier for FDA to inspect IRBs and to convey information to IRBs," HHS' Unified Agenda for 2002 explains. FDA is also endorsing a voluntary IRB accreditation system...
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Lilly hopes to be ready for a re-inspection of its intramuscular Zyprexa production facility in mid-May, ahead of the late June user fee deadline for a decision on the new formulation of the antipsychotic.